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Although well-designed prospective trials are generally lacking, intravenous immunoglobulins (IVIG) seem an
effective adjuvant treatment for autoimmune bullous skin diseases. Here, efficacy of IVIG monotherapy was
compared with corticosteroid treatment in mice with immunization-induced experimental epidermolysis bullosa
acquisita (EBA), an autoimmune bullous skin disease characterized by autoantibodies against type VII collagen.
We found that IVIG significantly ameliorated clinical disease severity and skin neutrophil infiltration compared
with vehicle-treated mice, whereas methylprednisolone showed comparatively less pronounced effects. Efficacy
of IVIG was accompanied by reduced levels of autoantibodies, a shift toward noncomplement-fixing
autoantibodies, and lower complement deposition at the dermal–epidermal junction. In addition, peripheral
Gr-1-positive cells of IVIG-treated animals showed reduced expression of the activating Fcg receptor IV, which we
recently described as a major mediator of tissue injury in experimental EBA. These data show that treatment with
IVIG is superior to systemic corticosteroids in experimental EBA and that the effects of IVIG are pleiotropic
involving modulation of both the adaptive and innate immune response, although the detailed mode of action of
IVIG in this model remains in need of further elucidation.
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INTRODUCTION
Epidermolysis bullosa acquisita (EBA) is an autoimmune
disease characterized by circulating and tissue-bound auto-
antibodies targeting the noncollagenous domain 1 of type VII
collagen of the dermal–epidermal junction (DEJ), thereby
leading to chronic subepidermal blistering (Woodley
et al.,1984, 1988; Chen et al., 2012). The pathogenic
relevance of (auto)antibodies against type VII collagen has
been conclusively shown ex vivo and in experimental animal
models (Ludwig, 2013). In these experimental models of EBA,
autoantibodies alone are not sufficient to induce blisters but
require an Fc-dependent engagement of inflammatory factors
(Ludwig, 2013). Both adaptive and innate components of the
immune system are regarded as being important for
pathogenesis in experimental EBA, including (i) B cells as
precursors of autoantibody-producing plasma cells and
possibly as antigen-presenting cells (Iwata et al., 2013); (ii)
autoreactive T cells controlling the production of pathogenic
autoantibodies (Sitaru et al., 2010; Iwata et al., 2013); (iii)
dendritic cells and macrophages, together with B cells,
inducing an autoreactive CD4 helper T-cell response (Iwata
et al., 2013); (iv) alternative complement generating a
proinflammatory and chemotactic environment in the skin
(Mihai et al., 2007); and (v) Fcg receptor (Fcg) IV-dependently
(Kasperkiewicz et al., 2012) activated neutrophils directly
causing tissue injury by proteolytic degradation of skin basal
membrane zone components (Shimanovich et al., 2004;
Chiriac et al., 2007). Experimental EBA, which mimics both
the autoimmune response and immunopathological,
histological, and clinical findings of patients with the
inflammatory type of EBA, can be induced in susceptible
mice by immunization with recombinant murine type VII
collagen (Sitaru et al., 2006; Iwata et al., 2013).
Current therapy for autoimmune bullous skin diseases
includes a range of options, most of them comprising
conventional immunosuppressive therapy. However, treat-
ment of patients with these diseases is a daunting task as
the different drugs used, especially in widespread and
recalcitrant patients with EBA, usually do not produce a
prolonged clinical remission and can have hazardous side
effects (Kasperkiewicz and Schmidt, 2009; Chen et al., 2012).
Therefore, there remains substantial unmet medical need in
the treatment of EBA.
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Intravenous immunoglobulins (IVIG) are therapeutic com-
pounds prepared from pooled normal polyspecific IgG
of human individuals. In addition to their use as a standard
replacement therapy in patients with primary and some
secondary immunodeficiencies, IVIG treatment has been
established as an effective and safe therapy for a number of
autoimmune-inflammatory diseases, such as immune throm-
bocytopenia, Guillain–Barre syndrome, multiple sclerosis,
myasthenia gravis, and Kawasaki disease (Rezaei et al.,
2011). IVIG has also been demonstrated to be effective in
patients with autoimmune skin diseases like dermatomyositis,
systemic lupus erythematosus, and autoimmune bullous skin
diseases, including EBA (Amagai et al., 2009; Ishii et al., 2010;
Rezaei et al., 2011). However, because of the rarity and
severity of the latter diseases, well-designed prospective trials
are generally lacking, with the exception of one controlled
study of IVIG therapy in pemphigus (Amagai et al., 2009). In
addition, the immunomodulatory mechanisms of action of
IVIG in autoimmune bullous skin disorders are complex and
not fully understood (Ishii et al., 2010), further underscoring
the need to establish the real potential of IVIG in these
diseases. Therefore, the aim of our study was to investigate
the impact of IVIG on mice with experimental EBA.
RESULTS
IVIG treatment reduces clinical and histological disease severity
in experimental EBA
After clinical EBA manifestation, mice were allocated to
phosphate-buffered saline (PBS; vehicle, n¼44), methylpredni-
solone (MP, n¼28), and IVIG (n¼38) treatment and investi-
gated for clinical and histological disease during a 4-week
period. The clinical courses of the different experimental groups
indicate that both MP and IVIG are effective treatments for EBA,
with the latter being superior (Figure 1a–e and Supplementary
Figure S1 online). In detail, although a significant number (71%)
of MP-treated mice reached normalized relative clinical scores
of p1.5, a significant clinical remission rate (i.e., normalized
relative scores o1.0) was only achieved in the IVIG treatment
group (Table 1). In addition, when calculated the area under the
curve, only IVIG-treated mice demonstrated significantly less
disease severity throughout the treatment course when com-
pared with other mouse groups (Figure 1b). Lower doses of MP
(2 or 10 mg kg 1 day1) had no therapeutic effect at all in this
experimental setting (data not shown). Furthermore, compar-
ison of human and mouse IVIG preparations showed similar
clinical effects: in a separate experiment, compared with PBS-
treated control mice (n¼12), overall clinical disease severity
was reduced by 47% using human IVIG (n¼7, P¼0.014) and
by 48% using mouse IVIG (n¼13, P¼ 0.026) by the end of a
4-week treatment period.
Histopathological analysis of ear skin demonstrated that
subepidermal blister formation and dermal inflammatory cell
infiltration were milder or absent in IVIG-treated mice com-
pared with the other groups (Figure 1f–h). The myeloperox-
idase (MPO) level in the skin of IVIG- but not MP-treated mice
was significantly lower in comparison with control mice,
although a nonsignificant tendency toward some reduction
was found in the corticosteroid group (Figure 1i).
Discontinuation of therapy is followed by some less progressive
disease course in IVIG- but not MP-treated mice compared
with vehicle-injected animals
Next, we followed up a subgroup of 8 IVIG- and 11 vehicle-
treated mice for another 8 weeks after completion of the
4-week treatment period. While the mean extent of skin
lesions significantly increased (by up to B4-fold compared
with treatment start) within the 4-week treatment period, a
further significant mean increase (by up toB8-fold compared
with treatment start) in disease severity was observed in
vehicle-treated mice between weeks 4 and 12 after last PBS
injection. In contrast, disease progression was suppressed in
IVIG-treated animals during the treatment period, and after
stopping IVIG therapy clinical disease continuously worsened,
but this was not statistically significant. In detail, disease
progression, stable disease, and healing of skin lesions were
observed in 7, 3, and 1 of 11 control mice and in 4, 1, and
3 of 8 IVIG-treated animals, respectively. In addition, direct
comparison of control with IVIG-treated mice revealed sig-
nificant differences in the extent of disease for up to 3 weeks
following treatment but not any longer by the end of the
observation period (Figure 2).
Moreover, a smaller subgroup of 3 MP- and 4 vehicle-
treated mice was followed up for another 7 weeks after an
extended treatment period of 5 weeks intended for a poten-
tially more enhanced therapeutic response. A significant
mean disease progression (by up toB2.5-fold compared with
treatment start) was only found in control mice during the
treatment period, and direct comparison with MP-treated mice
revealed a trend toward a significant difference (P¼0.06) in
the extent of disease within the treatment phase but not any
longer during post-treatment follow-up (P¼ 0.53) (Supplemen-
tary Figure S2 online).
IVIG treatment is associated with reduced levels of
autoantibodies and complement deposition, as well as
with modulation of autoantibody isotypes
Compared with PBS-treated mice, ELISA levels of circulating
anti-type VII collagen IgG autoantibodies were found to be
significantly lower in IVIG-treated animals (Figure 3a), which
showed relatively stable IVIG concentrations over the obser-
vation period (Supplementary Figure S3 online). In contrast,
mouse total serum IgG levels remained largely unchanged
after IVIG treatment (Figure 3b). Adding of different doses of
IVIG (0.1–20 mg ml1) to the type VII collagen-specific ELISA
did not alter the optical density readings, ruling out any
possible interference of IVIG with this assay (data not shown).
The staining intensity of skin basal membrane-bound IgG as
well as of complement C3 was significantly fainter in mice
that received IVIG, as measured by direct immunofluores-
cence microscopy (Figure 3c and d). Moreover, deposition of
complement-fixing antibodies (IgG2b and IgG2c) at the DEJ
was significantly reduced in IVIG-treated EBA mice compared
with control mice, whereas noncomplement-fixing antibody
(IgG1) deposition was not altered (Figure 3e and f). This
resulted in a higher (IgG2bþ IgG2c)/IgG1 ratio in the PBS-
treated animals compared with IVIG-treated mice (Figure 3g).
In contrast, skin samples of all three experimental groups
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showed no marked deposition of IgG3 at the DEJ (data not
shown), and there was no difference between PBS- and
MP-treated mice regarding circulating autoantibodies, C3 skin
deposits, and tissue-bound total IgG (Figure 3a, c, and d)
including IgG1, IgG2b, and IgG2c isotypes (data not shown).
FccRIV expression on Gr-1-positive cells is reduced in
IVIG-treated mice
FcgRIV has been recently implicated in the pathogenesis of
tissue injury in experimental EBA (Kasperkiewicz et al., 2012).
To investigate the association between disease reduction by
IVIG and the expression of this activating FcgR on leukocytes,
flow cytometric analysis of peripheral blood cells was per-
formed. Our data revealed that FcgRIV on Gr-1-positive cells
was significantly reduced by more than 2-fold in IVIG-treated
mice compared with PBS-treated animals (Figure 4a and b).
DISCUSSION
This study offers preliminary evidence that IVIG may exert
therapeutic activity in experimental EBA and that the mechan-
isms responsible for this effect are attributed to immuno-
modulatory effects on both adaptive and innate immune
mechanisms.
In our experiments, the impact of IVIG on clinical and
histological EBA disease was compared with conventional
immunosuppressive therapy using systemic MP over a 4-week
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Figure 1. Intravenous immunoglobulins (IVIG) treatment improves clinical and histological disease in mice with experimental epidermolysis bullosa acquisita
(EBA). Clinical scores were calculated as the percentage of the body surface area covered by EBA lesions and normalized to 1 before the start of treatment and after
reaching scores of X2%. (a) Mean scores are shown as clinical courses of phosphate-buffered saline (PBS)-, methylprednisolone (MP) (20 mg kg day 1 i.p.)-, and
IVIG (2 g kg 1 once per week i.p.)-treated mice during a 4-week treatment period. (b) Calculation of the area under the curve (AUC) revealed that the disease
severity of IVIG- but not MP-treated mice was significantly reduced compared with nontreated animals. (c–e) Representative clinical and (f–h) histological
presentations from PBS-, MP-, and IVIG-treated mice, respectively, at the end of the 4-week treatment period. (i) Comparison of the dermal neutrophil infiltration
between the different treatment groups revealed a significantly lower skin myeloperoxidase (MPO) level in the IVIG-treated mice only. Significances were
calculated with ANOVA followed by an all pairwise multiple comparison procedure (Dunn’s method) and expressed as mean±SEM (28–44 and 10–13 mice per
group for clinical and MPO analysis, respectively). *Po0.05 (in a, each first and second asterisk corresponds to Po0.05 between PBS-treated mice and IVIG- or
MP-injected animals, respectively; ns, not significant). Scale bars¼ 100mm.
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treatment period. We found that both clinical disease severity
and skin neutrophil infiltration were significantly ameliorated
after IVIG monotherapy compared with vehicle-treated mice,
whereas daily high dose MP showed comparatively less potent
effects.
Systemic corticosteroid therapy, commonly used in doses of
1–2 mg kg day 1 prednisolone equivalent, may be a sole
treatment in some patients with EBA, although many cases
do not respond to this regimen and require a combination
with additional immunosuppressive agents (Kasperkiewicz
and Schmidt, 2009; Chen et al., 2012). Similarly, a mono-
therapy with MP at a dose of 2 and even 10 mg kg day 1 had
no therapeutic effect at all in our study (data not shown).
Only a 10 times higher dose compared with patients (i.e.,
20 mg kg day1) was effective, which may reflect therapy
resistance in EBA, especially in the context of our
experimental setting.
IVIG is most commonly applied to patients with EBA in a
dose of 400 mg kg day 1 over 5 days in monthly intervals
(Ishii et al., 2010). Assuming that experimental EBA represents
a therapy-refractory model, we chose a more rigorous
treatment regimen with a dose of 2 g kg 1 IVIG given as
bolus for four times in weekly intervals, although a similar
intense IVIG dosing of up to 3 g kg1 divided over 3 days and
repeated every 2 weeks has also been reported in pemphigoid
patients (Foster and Ahmed, 1999). While EBA progressed in
PBS-treated control mice, approximately a third of the IVIG-
treated mice showed a clinical remission during the 4-week
treatment period, which was about twice the number as
compared with MP-treated animals, although timing of
response to treatment was similar in MP- and IVIG-treated
mice. In addition, post-treatment follow-up analysis revealed
that there was some less severe but not arrested disease
progression in IVIG- compared with vehicle-treated mice, an
effect that could not be reproduced in a subgroup of MP-
treated mice, which was, however, limited in size. In more
detail, a direct comparison of PBS- with IVIG-treated EBA
mice revealed significant differences in disease extent lasting
around 3 weeks, but no longer, after discontinuation of
treatment. It is tempting to speculate that this observation is
at least partly related to the known 3-week half-life of IVIG,
supporting recommendations for 3–4-week interval periods
between IVIG treatment cycles in patients with autoimmune
bullous diseases (Ishii et al., 2010). It remains to be clarified,
whether prolongation of this 4-week therapy by additional
IVIG treatment cycles in such intervals can maintain the
clinical response in our model. Our data are in agreement
with the limited information on the use of IVIG in EBA
patients, in which IVIG led to clinical improvement within a
few months in the majority of published cases (Ishii et al.,
2010). However, as in most of these patients, IVIG was
combined with systemic corticosteroids and/or additional
immunosuppressive therapy (Ishii et al., 2010), the clinical
effects attributed to either drug alone cannot be clearly
distinguished. On the other hand, it has to be emphasized
that individual mice did not respond to therapy with IVIG,
which may correspond to the nonconstant efficacy of IVIG
treatment in EBA patients as observed in clinical practice.
Along with the clinical and histological improvement in
IVIG-treated mice, reduced levels of circulating and skin-
bound anti-type VII collagen autoantibodies were found com-
pared with control mice. Interestingly, IgG subclass analysis
demonstrated a reduced deposition of complement-fixing
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Figure 2. IVIG attenuate but do not arrest post-treatment disease progression
in EBA mice. The mean extent of skin lesions significantly increased within the
4-week treatment period and a further significant mean increase in disease
severity was observed in a subgroup of vehicle-treated mice which were
followed for 8 additional weeks following last PBS injection (indicated by
Po0.05 in the upper brackets). In contrast, disease progression was suppressed
in a subgroup of IVIG-treated animals during the treatment period, and after
discontinuation of IVIG therapy clinical disease continuously worsened, but
this was not statistically significant (indicated by ns in the lower brackets).
Direct comparison of control with IVIG-treated mice revealed significant
differences in disease extent for up to 3 weeks after treatment but not any
longer by the end of the observation period. Significances were calculated with
the Wilcoxon rank sum test and repeated measure ANOVA and expressed as
mean±SEM (8–11 mice per group). *Po0.05 (referred to differences between
PBS- and IVIG-treated animals).
Table 1. Clinical response rates of PBS-, methylprednisolone-, and IVIG-treated EBA mice
Experimental groups Normalized relative clinical score of o1.0 Normalized relative clinical score of p1.5
Week 1 2 3 4 1 2 3 4
PBS (n¼ 44) 7% 5% 5% 7% 45% 25% 20% 14%
Methylprednisolone 20 mg kg 1 (n¼ 28) 18% 29% 18% 18% 71%* 54%* 29% 50%*
IVIG 2 g kg1 (n¼ 38) 37%* 37%* 29%* 34%* 84%* 55%* 53%* 58%*
Abbreviation: EBA, epidermolysis bullosa acquisita; IVIG, intravenous immunoglobulins; PBS, phosphate-buffered saline.
*Po0.01 as calculated by logistic regression analysis.
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IgG2 autoantibodies and complement C3 at the DEJ, whereas
noncomplement-fixing IgG1 autoantibodies were unaltered by
IVIG treatment. This resulted in a significantly decreased
(IgG2bþ IgG2c)/IgG1 ratio. In this context, it is important to
point out that the proinflammatory complement-fixing IgG
autoantibodies have been recently shown to be induced in
Th1-polarized lymph nodes of EBA-susceptible mice and that
resistance to experimental EBA induction is known to be
associated with a Th2-type response with a predominant
generation of nonpathogenic IgG1 autoantibodies (Hammers
et al., 2011). Interestingly, a sophisticated Th2 pathway has
recently been proposed to mediate IVIG’s anti-inflammatory
effects (Anthony et al., 2011), which may also account for the
observed favorable IgG class shift toward the noncomplement-
fixing IgG isotypes in our IVIG-treated mice. Considering the
reduced deposition of C3 at the DEJ, it is yet unknown
whether this effect is due to the lowered levels of
complement-fixing autoantibodies, a direct inhibitory action
of IVIG on complement components or their activation, or
combined actions.
In experimental EBA, neutrophils have been shown to
critically contribute to autoantibody-induced tissue damage
within the DEJ by the release of phagocyte-derived reactive
oxygen species and matrix metalloproteinases (Shimanovich
et al., 2004; Chiriac et al., 2007). Recent findings of our
laboratory showed a major dependency of this tissue injury on
the activating FcgRIV expressed on neutrophils. Mice lacking
FcgRIV were completely protected from the disease induced
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Figure 3. IVIG reduce circulating autoantibodies and skin-bound immunoreactants in EBA mice. (a) IVIG- but not MP-treated mice showed significantly
lower levels of circulating anti-type VII collagen (COL7)-specific IgG compared with PBS-treated mice at the end of the 4-week treatment period, as shown by
ELISA. (b) In contrast, IVIG had no significant impact on the amount of total circulating IgG. (c, d) Significantly lower staining intensity of skin basal membrane-
bound IgG and C3 was found in IVIG- but not MP-treated mice compared with PBS-treated mice at the end of the 4-week treatment period, as shown by
direct immunofluorescence microscopy. (e, f) Deposition of complement fixing IgG2b/c but not noncomplement-fixing IgG1 at the dermal–epidermal junction
was significantly reduced in IVIG- compared with PBS-treated mice at the end of the 4-week treatment period, as shown by direct immunofluorescence
microscopy. (g) A significantly higher (IgG2bþ IgG2c)/IgG1 ratio obtained from skin evaluation was found in the PBS-treated animals compared with IVIG-treated
mice. Significances were calculated with ANOVA followed by an all pairwise multiple comparison procedure (Dunn’s method) and expressed as mean±SEM
(38–44 mice per group). *Po0.05. Scale bars¼ 50mm.
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by the passive transfer of anti-type VII collagen IgG
(Kasperkiewicz et al., 2012). In addition, a higher FcgRIV
expression was found on peripheral leukocytes of EBA-suscep-
tible mice compared with nonsusceptible strains (Hammers
et al., 2011). In our current experiments, we could show that
the expression of this key activating receptor on peripheral Gr-
1-positive cells was significantly reduced in IVIG-treated EBA
mice compared with PBS-treated animals, which may result in
a compromised FcgR-dependent activation status of these
effector cells in EBA.
The mode of action of IVIG in autoimmune diseases is still
not determined precisely but is likely to involve multifactorial
mechanisms. It has been proposed that the immunomodula-
tory effects of IVIG can be mediated by its Fab fragments
(i.e., recognition and neutralization of specific, pathogenically
relevant epitopes and neutralization of autoantibodies by anti-
idiotype antibodies) or/and the Fc portion (i.e., inhibition of
activating FcgRs and the neonatal FcR or induction of the
inhibitory FcgRIIB) (Schwab and Nimmerjahn, 2013). With
regard to autoimmune blistering skin diseases, only a few
experimental models have been published to clarify the exact
mode of action of IVIG (Ishii et al., 2010). Using mouse
models of bullous pemphigoid and pemphigus it was
demonstrated that the effects of IVIG are mainly mediated
by the saturation of the neonatal FcR responsible for antibody
recycling (Li et al., 2005), via anti-desmoglein anti-idiotypic
antibodies (Mimouni et al., 2005, 2010), and through inhi-
bition of apoptolysis by upregulation of endogenous caspase
and calpain inhibitors (Arredondo et al., 2005). However, in
contrast to our active immunization-induced EBA mouse
model, in all these studies, a passive transfer of pathogenic
antibodies was used to induce disease. These passive models,
which do not fully reflect the situation in patients, are limited
by the use to solely study IVIG’s direct interference with
antibodies/receptors and IVIG effects on antibody-triggered
effector events but not on upstream immune processes leading
to autoantibody production. The detailed mechanisms of
how IVIG affect such immune responses in the active mouse
model of EBA yet remain to be clarified.
It also remains not completely understood what mechan-
isms could explain the clinical effects of MP in our model,
which were, however, only moderate and less pronounced
compared with those seen with IVIG treatment. This is
especially obscure considering the fact that circulating
autoantibodies and tissue-bound immunoreactants were not
influenced by the corticosteroid treatment. However, one
possible explanation may be the observed nonsignificant
tendency toward some reduction in the activation status of
dermal neutrophils in MP-treated mice, as measured by the
MPO level. In this context, it is worth mentioning a recent
study, which showed that MP is able to block autoantibody-
induced tissue damage in experimental models of bullous
pemphigoid and EBA through inhibition of extracellular
signal-regulated kinases 1 and 2–, p38 mitogen–activated
protein kinase–, and Akt-induced neutrophil activation
(Hellberg et al., 2013). Moreover, other known pathogenic
factors in EBA that have not been further investigated in our
experiments, including but not limited to T cells, dendritic
cells, and macrophages (Sitaru et al., 2010; Iwata et al., 2013),
might have been, at least to some degree, additionally affected
by MP.
In conclusion, our results suggest that IVIG treatment is
superior to systemic corticosteroids in controlling disease acti-
vity in experimental EBA and that the effects of this drug
are mediated by modulation of both adaptive (reduction in
autoantibodies and modulation of their isotypes toward non-
complement-fixing autoantibodies) and innate (reduction
in complement deposition and downregulation of FcgRIV on
Gr-1-positive effector cells) immune responses. Further studies
aiming to dissect the exact mode of action of IVIG in
experimental EBA are needed.
MATERIALS AND METHODS
Mice
SJL mice aged 6–8 weeks were purchased from Charles River
Laboratories (Sulzfeld, Germany). Animal experiments were approved
by local authorities of the Animal Care and Use Committee
(Kiel, Germany) and performed by certified personnel.
Production of autoantigen
The recombinant fragment of murine type VII collagen (mCOL7C;
amino acids 757–967) was prepared as described previously (Sitaru
et al., 2005, 2006). Recombinant tagged fragments GST-mCOL7C
and His-mCOL7C were produced using a prokaryotic expression
system and purified by glutathione and metallochelate affinity
chromatography, respectively (Sitaru et al., 2005, 2006).
Induction of EBA and phenotype analysis
Experimental EBA was induced in mice by active immunization, as
described previously (Kasperkiewicz et al., 2010, 2011). Briefly, mice
were injected subcutaneously in the hind footpads with a single
injection of 100ml of emulsion containing 60mg of GST-mCOL7C
in TiterMax (Alexis Biochemicals, Lo¨rrach, Germany). Mice were
examined every week for their general condition and for cutaneous
lesions (i.e., erythema, blisters, erosions, and crusts). Disease severity
was calculated as the percentage of the body surface area affected
by skin lesions.
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Figure 4. IVIG decrease FccRIV expression on circulating Gr-1-positive
cells in EBA mice. (a) Significantly lower expression (mean fluorescence
intensity, MFI) of FcgRIV on peripheral blood Gr-1-positive cells was observed
in IVIG-treated compared with PBS-treated mice after the 4-week treatment
period. (b) Representative corresponding flow cytometric analysis.
Significances were calculated with a t-test and expressed as mean±SEM
(seven mice per group). *Po0.05.
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Treatment and follow-up of mice
If X2% of the body surface area was affected by EBA lesions, mice
were randomly allocated into three experimental groups: (1) PBS
(vehicle) treatment, (2) MP (20 mg kg day 1 i.p.) (Urbason, Sanofi-
Aventis, Frankfurt, Germany), and (3) human IVIG (2 g kg 1 once per
week i.p.) (Intratect, Biotest, Dreieich, Germany) or mouse IVIG
(2 g kg 1 once per week i.p.) (mouse IgG Lyophilized Fractionated
Method preparation, Innovative Research, Dunn Labortechnik
GmBH, Asbach, Germany). MP and IVIG were given over a 4-week
treatment period in the vast majority of experiments. To investigate
the disease course after completion of the 4-week treatment period, a
subgroup of PBS- (n¼ 11) and IVIG-injected mice (n¼ 8) was
followed up for 8 additional weeks. A smaller subgroup of PBS-
(n¼ 4) and MP-injected mice (n¼ 3) was followed up for 7 additional
weeks after receiving a 5-week treatment.
Histopathology
Biopsies of ear skin were prepared for examination by histopathology,
as described previously (Sitaru et al., 2005). Briefly, biopsies collected
from experimental animals were fixed in 4% buffered formalin, and
sections from paraffin-embedded tissues were stained with
hematoxylin and eosin.
Direct immunofluorescence microscopy
Biopsies of ear skin were prepared for examination by direct
immunofluorescence microscopy, as described previously (Sitaru
et al., 2005). Briefly, total IgG, IgG subclasses (IgG1, IgG2b, IgG2c,
IgG3), and complement C3 deposits were detected by direct
immunofluorescence microscopy on frozen sections prepared
from tissue biopsies using 100-fold diluted FITC-labeled antibodies
specific to mouse IgG (Dako, Hamburg, Germany) and its sub-
classes (all from BD Bioscience, Heidelberg, Germany), as well as
to murine C3 (MP Biomedicals, Solon, OH). The staining intensity of
immunoreactants in the skin of mice was quantified with ImageJ
software (National Institutes of Health, Bethesda, MD).
MPO assay
Determination of neutrophil infiltration of murine skin by the MPO
assay was performed as described (Bradley et al., 1982; Ludwig et al.,
2011). Briefly, the left ear was removed and MPO was extracted by
homogenization in a buffer containing 0.1 M Tris-Cl, pH 7.6, 0.15 M
NaCl, and 0.5% hexadecyl trimethylammoniumbromide (Sigma,
Munich, Germany). MPO activity in the supernatant fraction was
measured by the change in optical density at 460 nm. A standard
reference curve was established using known concentrations of
purified MPO (Sigma).
Determination of circulating anti-type VII collagen
autoantibodies and human IVIG by the enzyme-linked
immunosorbent assay
Circulating autoantibodies against type VII collagen were detected by
incubating diluted serum samples on His-mCOL7C-coated plates. To
measure serum levels of antibodies against COL7 or to peptides,
ELISA using synthetic or recombinant peptides of COL7 as target
antigens was performed as described, with minor modifications
(Sitaru et al., 2006). To rule out any possible interference of IVIG
with this ELISA, IVIG (0.1–20 mg ml 1) were added to selected sera
prior to determination of autoantibody levels by this assay. The
concentration of human and mouse IgG was determined in plasma of
mice using a human and mouse IgG ELISA kit, respectively, as per the
manufacturer’s instructions (Human IgG ELISA Quantitation Set,
Bethyl Laboratories, Montgomery, TX; and mouse IgG ELISA
Quantitation Set, Bethyl Laboratories).
Detection of FccRIV on peripheral leukocytes by flow cytometry
Peripheral blood was taken with heparin sodium for flow cytometric
analysis (Ratiopharm, Ulm, Germany). Single cell suspension was
prepared by standard methods. Whole blood (100ml) was stained
with FITC-conjugated rat anti-mouse Ly-6C/Ly-6G (Gr-1; RB6-8C5,
BD Pharmingen, San Diego, CA) and Alexa Fluor 647-conjugated
anti-FcgRIV antibody, Institute of Genetics, Department of Biology,
University of Erlangen-Nuremberg, Erlangen, Germany (clone 9E9,
prepared as described previously (Nimmerjahn et al., 2005)) for
30 minutes in the dark at 4 1C. Rat IgG1-FITC and Armenian hamster
IgG-APC (both from eBioScience, Frankfurt am Main, Germany) were
used as isotype control antibodies, respectively. Cells were analyzed
by flow cytometry on a BD LSRII flow cytometer using the FACSDiva
software (BD Bioscience). Gates were set around granulocytes on the
basis of their forward/sideward light scatter pattern and Gr-1
expression. Surface marker expression levels were expressed as the
geometrical mean fluorescence intensity on granulocytes.
Statistics
Statistical calculations were performed using SigmaPlot (Systat Soft-
ware, Chicago, IL). A P-value o0.05 was considered statistically
significant.
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